KR102949226B1 - D1 양성 알로스테릭 조절제로서의 치환된 테트라히드로이소퀴놀린 유도체 - Google Patents

D1 양성 알로스테릭 조절제로서의 치환된 테트라히드로이소퀴놀린 유도체

Info

Publication number
KR102949226B1
KR102949226B1 KR1020227002603A KR20227002603A KR102949226B1 KR 102949226 B1 KR102949226 B1 KR 102949226B1 KR 1020227002603 A KR1020227002603 A KR 1020227002603A KR 20227002603 A KR20227002603 A KR 20227002603A KR 102949226 B1 KR102949226 B1 KR 102949226B1
Authority
KR
South Korea
Prior art keywords
compound
formula
methyl
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227002603A
Other languages
English (en)
Korean (ko)
Other versions
KR20220029687A (ko
Inventor
앤 바라드
Original Assignee
유씨비 바이오파마 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨비 바이오파마 에스알엘 filed Critical 유씨비 바이오파마 에스알엘
Publication of KR20220029687A publication Critical patent/KR20220029687A/ko
Application granted granted Critical
Publication of KR102949226B1 publication Critical patent/KR102949226B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227002603A 2019-07-01 2020-06-29 D1 양성 알로스테릭 조절제로서의 치환된 테트라히드로이소퀴놀린 유도체 Active KR102949226B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
EP19183641.0 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (2)

Publication Number Publication Date
KR20220029687A KR20220029687A (ko) 2022-03-08
KR102949226B1 true KR102949226B1 (ko) 2026-04-06

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002603A Active KR102949226B1 (ko) 2019-07-01 2020-06-29 D1 양성 알로스테릭 조절제로서의 치환된 테트라히드로이소퀴놀린 유도체

Country Status (24)

Country Link
US (1) US12358890B2 (https=)
EP (1) EP3993795B1 (https=)
JP (1) JP7618597B2 (https=)
KR (1) KR102949226B1 (https=)
CN (1) CN114008032B (https=)
AR (1) AR119317A1 (https=)
AU (1) AU2020299705B2 (https=)
BR (1) BR112021022379A2 (https=)
CA (1) CA3139622A1 (https=)
CL (1) CL2021002949A1 (https=)
CO (1) CO2021017740A2 (https=)
EC (1) ECSP22007557A (https=)
IL (1) IL289317B2 (https=)
MA (1) MA56445A (https=)
MX (1) MX2021015872A (https=)
MY (1) MY210362A (https=)
PE (1) PE20220373A1 (https=)
PH (1) PH12021552819A1 (https=)
SA (1) SA521431274B1 (https=)
SG (1) SG11202112539XA (https=)
TW (1) TWI842923B (https=)
UA (1) UA130613C2 (https=)
WO (1) WO2021001286A1 (https=)
ZA (1) ZA202109194B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2976784T3 (es) 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
EP4304577A1 (en) * 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193781A1 (en) 2013-05-30 2014-12-04 Eli Lilly And Company 3,4-dihydroisoquinolin-2(1h)-yl compounds
WO2016055479A1 (en) 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
WO2017178377A1 (en) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679735A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
IN2014CN03234A (https=) 2011-11-03 2015-07-03 Merck Sharp & Dohme
JP7090099B2 (ja) * 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193781A1 (en) 2013-05-30 2014-12-04 Eli Lilly And Company 3,4-dihydroisoquinolin-2(1h)-yl compounds
WO2016055479A1 (en) 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
WO2017178377A1 (en) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., 2019, Vol. 62, pp. 128-140

Also Published As

Publication number Publication date
CA3139622A1 (en) 2021-01-07
JP2022537994A (ja) 2022-08-31
IL289317B1 (en) 2025-05-01
EP3993795B1 (en) 2026-04-22
IL289317B2 (en) 2025-09-01
SG11202112539XA (en) 2021-12-30
IL289317A (en) 2022-02-01
ZA202109194B (en) 2023-11-29
TWI842923B (zh) 2024-05-21
MA56445A (fr) 2022-05-11
AU2020299705B2 (en) 2026-03-19
WO2021001286A1 (en) 2021-01-07
CN114008032B (zh) 2023-11-10
PH12021552819A1 (en) 2022-09-28
ECSP22007557A (es) 2022-02-25
AR119317A1 (es) 2021-12-09
SA521431274B1 (ar) 2024-01-09
CL2021002949A1 (es) 2022-07-15
JP7618597B2 (ja) 2025-01-21
US20220251064A1 (en) 2022-08-11
US12358890B2 (en) 2025-07-15
CO2021017740A2 (es) 2022-01-17
BR112021022379A2 (pt) 2022-03-08
PE20220373A1 (es) 2022-03-16
UA130613C2 (uk) 2026-04-01
TW202115009A (zh) 2021-04-16
CN114008032A (zh) 2022-02-01
AU2020299705A1 (en) 2021-12-09
KR20220029687A (ko) 2022-03-08
EP3993795A1 (en) 2022-05-11
MX2021015872A (es) 2022-02-03
MY210362A (en) 2025-09-13

Similar Documents

Publication Publication Date Title
JP7510444B2 (ja) Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体
EP3442945B1 (en) Tetrahydroisoquinoline derivatives
KR102949226B1 (ko) D1 양성 알로스테릭 조절제로서의 치환된 테트라히드로이소퀴놀린 유도체
EP4263517B1 (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
RU2824527C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
JP2023551173A (ja) オクタヒドロイソキノリニル誘導体
RU2824581C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
HK40060812B (zh) 作为d1正变构调节剂的取代的四氢异喹啉衍生物
HK40060812A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931B (zh) 作为d1正变构调节剂的取代的四氢异喹啉衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)